CareDx Announces Revised Timeline to Its Offer to Acquire Allenex
Feb 29, 2016 07:26 am UTC| Business
BRISBANE, Calif., Feb. 29, 2016 -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic surveillance...
Delhaize Group press release - Capital structure disclosure
Feb 29, 2016 07:06 am UTC| Business
BRUSSELS, Belgium, Feb. 29, 2016 -- Delhaize Group discloses the information required under article 15, 1 and 18, 1 of the Belgian Law of May 2, 2007 regarding the disclosure of major shareholdings in listed companies...
Midatech Pharma Recognises International Rare Disease Day 2016
Feb 29, 2016 07:00 am UTC| Business
ABINGDON, Va., Feb. 29, 2016 -- Midatech Pharma (AIM:MTPH), (Nasdaq:MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas,...
AND signs important map license agreement with one of the largest European internet companies
Feb 29, 2016 06:37 am UTC| Business
AND realizes strong growth in revenue and profits in 2015 compared to 2014 AND has already locked in 2016 revenue which substantiates a marked growth rate compared to 2015 CAPELLE AAN DEN IJSSEL, the Netherlands, Feb....
Feb 29, 2016 06:22 am UTC| Business
CRESEMBA approval in U.S. and Europe and launched in the U.S. by Astellas Zevtera launched in major European countries Tumor checkpoint controller BAL101553 interim phase 2a (i.v.) study data reported and phase 1...
Feb 29, 2016 06:10 am UTC| Business
NEW YORK, Feb. 29, 2016 -- The long-beleaguered financial state of the maritime container-shipping industry will likely worsen in 2016, and the only thing apt to cure the industry's malaise is further consolidation....
Celyad to Host an Immuno-Oncology R&D Analyst Day on March 24th in New York City
Feb 29, 2016 06:00 am UTC| Business
Expert panel to present on next generation T-Cell therapy using the natural killer cell receptor NKG2DCelyad to present its immune-oncology portfolio with emphasis on the natural killer receptor T-Cell (NKR T-Cell) program...